Jul 26th 2012 - Edison Investment Research today published a report on Biotech Growth Trust (BIOG.L, LSE:BIOG, LON:BIOG) entitled "Further Strong Performance". In summary, the report says:
The Biotech Growth Trust (BIOG) has continued its strong track record of performance over the past 12 months, with share price and NAV total returns of 44.8% and 36.9% respectively. It has outperformed the NASDAQ Biotechnology Index (sterling adjusted) over the same period, and this has outperformed the broader market, returning 30.3% vs a fall of 3.8% for the FTSE All-Share Index. Despite share price gains, earnings growth leaves P/E valuations near 15-year lows. M&A support is likely to continue with 2012 marking a peak in patent expirations for large pharma companies who remain eager to re-fill their product pipelines.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »